Technology
Health
Biotechnology

Cytokinetics

$8.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-1.02%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Cytokinetics and other stocks, options, ETFs, and crypto commission-free!

About

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Read More The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Employees
130
Headquarters
South San Francisco, California
Founded
1997
Market Cap
483.71M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
375.98K
High Today
$9.24
Low Today
$8.71
Open Price
$8.91
Volume
228.79K
52 Week High
$10.44
52 Week Low
$5.75

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
US
North America

News

The Motley FoolMar 20

Here's Why Cytokinetics Stock Jumped Today

What happened Shares of Cytokinetics (NASDAQ:CYTK), a clinical-stage biopharmaceutical company, jumped in afternoon trading after its partner, Amgen (NASDAQ:AMGN), reported some good news. An improved outlook for Cytokinetics' lead candidate drove the stock 19% higher on Wednesday. So what Cytokinetics and Amgen have been working on new heart failure drugs since 2006, and omecamtiv mecarbil, the most advanced new drug candidate they've produced so far, took another step toward commercialization today. A...

1,802
Seeking AlphaMar 20

Large-scale study of Cytokinetics' omecamtiv mecarbil to continue unmodified

Cytokinetics (NASDAQ:CYTK) and collaboration partner Amgen (NASDAQ:AMGN) announce that their large-scale Phase 3 clinical trial, GALACTIC-HF, evaluating cardiac myosin activator omecamtiv mecarbil in ~8,000 heart failure patients will continue unchanged.

657
Markets InsiderMar 20

Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, March 20, 2019 (GLOBE NEWSWIRE) -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtivmecarbil continue without ch...

164

Earnings

-$0.75
-$0.63
-$0.52
-$0.40
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 25, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.